HCG in ectopic pregnancy: how the indicators change

Human chorionic gonadotropin is a placental hormone that appears in the blood shortly after implantation and increases during early pregnancy. For distinguishing between normal intrauterine and abnormal pregnancies, the hormone's dynamics over time, rather than a single value, is informative. This is especially important for pain and spotting in the first trimester, when clinical presentations overlap. [1]

A single blood test cannot reliably differentiate a viable intrauterine pregnancy from an ectopic pregnancy or a missed abortion because the ranges of values partially overlap. Interpretation is based on a combination of clinical examination, transvaginal ultrasound, and repeat hormone testing 48 hours later. [2]

Historically, a so-called discriminatory level was used—a hormonal threshold above which, in the case of a normal intrauterine pregnancy, the gestational sac should be visualized during transvaginal ultrasound. Current guidelines warn that relying solely on this threshold is dangerous, as the visualization point depends on the quality of equipment, the experience of the specialist, and the variability of early development. [3]

Practical conclusion: 48-hour hormone dynamics and transvaginal ultrasound results are assessed jointly. In cases of inconclusive findings, standardized monitoring algorithms with repeat testing and imaging are used. [4]

Biology and typical trajectories in early pregnancy

In a viable intrauterine pregnancy, the hormone rises rapidly in the first few weeks, then the rate of increase slows. The minimum expected increase over 48 hours depends on the initial level: the higher the starting value, the lower the minimum "normal" increase. This explains why a universal percentage is not applicable to all situations. [5]

Ectopic pregnancies exhibit varied trajectories: slow growth, plateaus, or irregular changes. A downward trend may indicate a non-viable pregnancy; however, even with decreased hormone levels, the risk of tubal rupture remains until the pregnancy resolves completely, requiring observation until a negative test is obtained. [6]

In cases of pregnancy of unclear localization, when the test is positive but the gestational sac is not visible in the uterus on ultrasound and the precise location is unclear, a serial measurement and repeat imaging algorithm becomes key. This approach reduces the risk of both delayed treatment and unnecessary intervention in a viable intrauterine pregnancy. [7]

Thus, for early diagnosis and choice of tactics, a systematic combination of data is needed: symptoms, vital signs, transvaginal ultrasound, hormone trajectory and standardized risk stratification. [8]

Table 1. Key definitions

Term	Meaning	What does this give to the doctor?
Ectopic pregnancy	Implantation of an embryo outside the uterine cavity	Risk of rupture and internal bleeding
Pregnancy of unknown location	The test is positive, ultrasound shows there is no fertilized egg in the uterus, the source has not been identified.	Starts a serial measurement and re-imaging protocol
Discriminatory level	The conditional threshold of the hormone above which, in a normal intrauterine pregnancy, visualization of the gestational sac is expected	Used with caution, not as the sole criterion
Attitude in 48 hours	Hormone value after 48 hours relative to the initial value	Helps to stratify risk in pregnancy of unclear location

Definitions are summarized from early pregnancy clinical guidelines. [9]

Why a single "discrimination level" threshold is unreliable

Guidelines emphasize that the absence of a gestational sac in the uterus with hormone levels near traditional thresholds is not sufficient to confidently diagnose an ectopic pregnancy without additional data. To minimize the risk of erroneous intervention in a normally developing pregnancy, some sources suggest using higher thresholds of approximately 3,500 international units per milliliter if a woman wants to minimize the risk of error, but the decision is always contextual. [10]

Visibility variability depends on the device's resolution, body type, uterine characteristics, and the earliest stages of pregnancy, when the gestational sac is still small despite the rising hormone levels. Therefore, the discrimination level is used only as an auxiliary concept and is always supplemented by 48-hour dynamics and repeat visualization. [11]

Emergency care policies also warn: ectopic pregnancy should not be ruled out solely based on hormone levels in the presence of an inconclusive ultrasound. It is important to return the patient for follow-up examinations according to a standardized schedule. [12]

Conclusion: The threshold approach is only suitable as a guideline, not as an independent diagnostic criterion. The key to safety is the hormone trajectory and repeat transvaginal ultrasound. [13]

Table 2. Discrimination Level: How to Use Safely

Paragraph	What to remember	Why is this important?
The threshold is not a sentence	The absence of a gestational sac at a level close to the threshold does not equal a diagnosis	Preventing erroneous interventions
The threshold is not universal	Visibility depends on technology and timing	Reducing false conclusions
Always check the dynamics	Change over 48 hours is more informative than a single number	Early detection of pathological trajectory
Re-visualization is mandatory	Clear control deadlines	Timely correction of tactics

Summary of modern clinical positions. [14]

Minimum Expected Growth in 48 Hours: What's "Normal"?

Large analyses have shown that the minimum expected hormone increase over 48 hours in a viable intrauterine pregnancy depends on the initial level: at values below 1500 international units per milliliter, the target is about 49%, at 1500-3000, about 40%, and at above 3000, about 33%. These are the lower percentiles, meaning that most viable pregnancies grow faster.[15]

Some reviews cite a minimum gain of approximately 35% over 48 hours as a "warning threshold," but this average benchmark does not replace a baseline-based approach. These differences highlight the need to evaluate a specific trajectory in the context of the starting point. [16]

If the increase over 48 hours is less than expected for a given baseline level, the likelihood of an ectopic pregnancy or a missed abortion increases significantly. A drop in hormone levels is more likely to indicate a missed abortion, but a full clinical context is essential for making a conclusion. [17]

No percentage by itself "makes a diagnosis." The decisive factors are a joint assessment of symptoms, transvaginal ultrasound results, and a standardized follow-up visit schedule. [18]

Table 3. Minimum expected weight gain in 48 hours in a viable intrauterine pregnancy

Baseline hormone level	Minimum expected increase in 48 hours
Below 1500 international units per milliliter	About 49%
1500-3000 international units per milliliter	About 40%
Above 3000 international units per milliliter	About 33%

According to research on the dynamics of early intrauterine pregnancy. [19]

Pregnancy of unknown location: 48-hour relationship and risk models

A practical tool is the 48-hour ratio, which is the hormone level after 48 hours relative to the baseline. At ratio values of approximately 1.66 and above, the likelihood of a viable intrauterine pregnancy is high; with a significant drop, the likelihood of a missed abortion is high; and the intermediate zone is associated with an increased risk of ectopic pregnancy. This is not a diagnosis, but rather part of risk stratification. [20]

Modern models for pregnancy of unclear location—for example, the updated M6 model—use the 48-hour ratio along with clinical variables to predict risk and plan follow-up. This helps safely schedule follow-up imaging and testing appointments. [21]

Algorithms always include repeat transvaginal ultrasound, even if the outcome is favorable, as rare exceptions are possible. The choice of interval between visits depends on symptoms and the initial level. [22]

This approach reduces the number of both missed ectopic pregnancies and unnecessary interventions for early intrauterine pregnancies.[23]

Table 4. 48-hour ratio in pregnancy of unclear localization: guidelines and actions

Attitude in 48 hours	Interpretation	The next step
Around 0.87 and below	A non-viable pregnancy is likely	Follow-up until a negative test is obtained according to the observation protocol
0.87-1.66	Intermediate zone, increased risk of ectopic pregnancy	Repeat transvaginal ultrasound, serial testing, low threshold for in-depth evaluation
1.66 and above	There is a high probability of a viable intrauterine pregnancy	A repeat ultrasound scan to confirm the location will be performed in the coming days.

According to research and practical reviews on pregnancy of unknown localization. [24]

How to combine ultrasound and hormones in an algorithm

The initial assessment includes symptoms, hemodynamics, and transvaginal ultrasound. If a gestational sac is visualized in the uterus, the strategy is determined based on viability. If not, a pregnancy of unknown location protocol is initiated, with repeat hormone measurements after 48 hours and repeat imaging. [25]

It's critical not to use hormone levels as a "filter" for ordering an ultrasound. If pain and bleeding are present, a transvaginal ultrasound is indicated regardless of the date. This speeds up diagnosis and reduces the risk of missing an ectopic pregnancy. [26]

After two hormone measurements and two imaging studies, most clinical scenarios become clear. If the trajectory is atypical and symptoms worsen, the threshold for diagnostic laparoscopy or targeted therapy is lower. [27]

The algorithm should be clear to the patient: specific timeframes for follow-up visits and criteria for immediate treatment in the event of deterioration. This approach reduces the risk of delayed care. [28]

Table 5. Diagnostic route for pregnancy of unclear localization

Step	What are we doing?	Target
1. Start	Transvaginal ultrasound and baseline hormone	Basic stratification
2. After 48 hours	Repeat hormone and clinical reassessment	Determine the trajectory
3. Re-visualization	Based on the results of step 2	Confirm localization
4. Solution	Observation, medication, or surgery	Personalized plan

Synthesis of recommendations for early pregnancy. [29]

Methotrexate drug treatment: who benefits and how to monitor it

Methotrexate is effective in carefully selected patients without signs of rupture or instability. The likelihood of success is lower with high initial hormone levels, the presence of fetal cardiac activity, and large lesion sizes. These factors are considered when choosing a strategy. [30]

Standard monitoring after methotrexate administration includes hormone measurements on the day of administration, days 4, and days 7. A decrease of at least 15% from day 4 to day 7 is expected. If the decrease is less, a repeat dose or surgical treatment is considered. Hormone levels are then monitored weekly until a negative test is obtained. [31]

Patients are advised on safety precautions: avoiding another pregnancy for approximately three months, discussing temporary discontinuation of folic acid supplements according to local protocol, avoiding alcohol and nonsteroidal anti-inflammatory drugs, and recognizing signs of worsening symptoms. Specific recommendations are clarified according to national guidelines. [32]

Even with declining hormone levels, the risk of rupture remains until the pregnancy is fully resolved. Therefore, emergency procedures are clearly discussed in advance. [33]

Table 6. Post-methotrexate monitoring

Day	What are we measuring?	Target benchmark	Further
Introduction day	Hormone, clinic	Original meaning	Training and warnings
Day 4	Hormone	A slight increase is allowed	Preparing the assessment for the 7th day
Day 7	Hormone	Decrease of 15% or more from day 4	If the reduction is insufficient, review the tactics
Then weekly	Hormone	Steady decline to negative test	Completion of observation

According to guidelines of professional societies and clinical protocols. [34]

Table 7. Factors that reduce the likelihood of success of methotrexate

Factor	Why is it important?
High baseline hormone levels	Lower probability of conservative resolution
Cardiac activity of the embryo	Surgical tactics are more often required
Large size of the hearth	Reduces the effectiveness of the drug regimen
Impossibility of reliable observation	Risk of missing deterioration and rupture

Based on the data from relevant manuals. [35]

When is expectant management acceptable?

In carefully selected patients without pain or signs of internal bleeding, with low and declining hormone levels and no signs of a progressive ectopic pregnancy, expectant management can be effective. Observation is carried out according to a strict schedule until complete resolution. [36]

Selection criteria include hemodynamic stability, willingness to make frequent visits, access to emergency care, and patient awareness of signs of deterioration. This approach reduces exposure to medications and surgeries in some patients. [37]

Even with favorable dynamics, clear instructions are needed: where and when to seek medical attention if pain, increased bleeding, dizziness, or weakness occur. This increases safety and reduces delays in assistance. [38]

Any deviation from the expected trajectory prompts reassessment and consideration of medical or surgical treatment. [39]

Table 8. Choice of tactics: observation, methotrexate or surgery

Situation	What do they choose more often?	Base
Low and decreasing hormone, no pain, stable condition	Watchful waiting	High chance of spontaneous resolution
Stable condition, no signs of rupture, initial parameters are moderate	Methotrexate	High probability of success with proper monitoring
Instability, signs of internal bleeding, suspected rupture	Emergency surgery	Preserving life and controlling bleeding

Summary logic according to modern manuals. [40]

When immediate surgical treatment is required

Unstable blood pressure, tachycardia, signs of intra-abdominal bleeding, and severe abdominal pain with symptoms of peritoneal irritation are indications for emergency surgery, regardless of hormone levels. Waiting for "better" results is unavoidable. [41]

If imaging reveals clear signs of a progressive ectopic pregnancy with bleeding or a high risk of rupture, surgical management ensures source control and saves lives. The team determines the strategy based on the specific anatomy. [42]

After surgery, hormone levels are monitored until a complete negative test is obtained, since residual trophoblastic tissue sometimes retains secretion and requires further observation. [43]

The safety rule remains the same: if the patient's condition worsens, she seeks emergency help immediately, without waiting for a scheduled test. [44]

Common Mistakes and Myths

Myth: "If the hormone level is above the threshold and the gestational sac is not visible, it is always an ectopic pregnancy." Fact: No. The threshold is a guideline; the decision is made based on the totality of the data and the dynamics over 48 hours with repeat visualization. [45]

Myth: “One test is enough to differentiate between an intrauterine and ectopic pregnancy.” Fact: One test is not reliable; the trajectory and visualization according to the protocol are more informative. [46]

Myth: "If the hormone level drops, there is no danger." Fact: The risk of rupture remains until the pregnancy is completely resolved, so observation continues until the test is negative. [47]

Myth: "Methotrexate works the same for everyone." Fact: Success depends on the initial hormone level, the size of the lesion, the presence of cardiac activity, and the ability to closely monitor it. [48]

A short algorithm for practice

1. In case of pain and bloody discharge in the first trimester - transvaginal ultrasound examination regardless of hormone levels. [49]
2. If visualization does not determine the localization, repeat the hormone test after 48 hours and repeat visualization according to the protocol for pregnancy of unclear localization. [50]
3. Assess the gain taking into account the baseline level and the 48-hour ratio, avoiding rigid reference to a single threshold. [51]
4. If methotrexate is chosen, monitor the hormone on days 4 and 7, expecting a decrease of at least 15% from day 4 to day 7, then weekly until a negative test. [52]